Sugi Predict

Sugi Predict / Targets / RBPJ

RBPJ

Recombining binding protein suppressor of hairless · Q06330 · RBPJ on Sugi Atlas →

4,288 patent compounds predicted against RBPJ, 2,706 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL3287597 SCHEMBL3287597 0.67 9/20
SCHEMBL4481848 SCHEMBL4481848 0.66 5/20
SCHEMBL4490697 SCHEMBL4490697 0.62 5/20
SCHEMBL3289613 SCHEMBL3289613 0.51 5/20
SCHEMBL3287204 SCHEMBL3287204 1.00 4/20
SCHEMBL3287399 SCHEMBL3287399 1.00 4/20
SCHEMBL3287605 SCHEMBL3287605 1.00 4/20
SCHEMBL3287889 SCHEMBL3287889 1.00 4/20
SCHEMBL3289545 SCHEMBL3289545 1.00 4/20
SCHEMBL3289687 SCHEMBL3289687 1.00 4/20
SCHEMBL3290276 SCHEMBL3290276 1.00 4/20
SCHEMBL3290428 SCHEMBL3290428 1.00 4/20
SCHEMBL3290519 SCHEMBL3290519 1.00 4/20
SCHEMBL3295115 SCHEMBL3295115 1.00 4/20
SCHEMBL4110243 SCHEMBL4110243 1.00 4/20
SCHEMBL3287598 SCHEMBL3287598 0.88 4/20
SCHEMBL3293651 SCHEMBL3293651 0.88 4/20
SCHEMBL4496795 SCHEMBL4496795 0.86 4/20
SCHEMBL3287247 SCHEMBL3287247 0.84 4/20
SCHEMBL4488196 SCHEMBL4488196 0.83 4/20

Clinical trials — most relevant to RBPJ by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Effect of Oral Supplementation With Curcumin (Turmeric) in Patients With Proteinuric Chronic Kidney Disease PHASE3COMPLETED
Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency PHASE2/PHASE3RECRUITING
sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer PHASE2UNKNOWN
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) PHASE2ACTIVE_NOT_RECRUITING
TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer PHASE2COMPLETED
SGI-110 and Donor Lymphocyte Infusions (DLI) After Allogeneic Stem Cell Transplantation PHASE2UNKNOWN
A Phase II Clinical Trial Evaluating the Combination of Olaparib and Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma PHASE2ACTIVE_NOT_RECRUITING
Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475 PHASE2COMPLETED
A Gene Transfer Study Inducing Fetal Hemoglobin in Sickle Cell Disease (GRASP, BMT CTN 2001) PHASE2ACTIVE_NOT_RECRUITING
FOLFOXIRI-based HAIC Combined With Fuquintinib as Late-line Treatment in Patients With CRLM：A Phase 2 Single-Arm Clinical Trial PHASE2COMPLETED
A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer PHASE2COMPLETED
Phase I/II Study of Recombinant Human Hepatocyte Growth Factor in Fulminant Hepatic Failure PHASE1/PHASE2UNKNOWN
A Phase I/II Study of Paclitaxel, Carboplatin and YM155 (Survivin Suppressor) in Subjects With Solid Tumors (Phase I) and Advanced Non-Small Cell Lung Carcinoma (Phase II) PHASE1/PHASE2COMPLETED
L19IL2/L19TNF in Skin Cancer Patients PHASE2UNKNOWN
Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC) PHASE1COMPLETED
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML PHASE1COMPLETED
ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors PHASE1WITHDRAWN
Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC EARLY_PHASE1RECRUITING
A Clinical Trial for the Safety and Efficacy of CD-801 in Patients With Advanced Hepatocellular Carcinoma EARLY_PHASE1COMPLETED
Emerging Role of NOTCH-related Long Non-coding RNA(s) as Biomarkers in Liquid Biopsy From Colorectal Cancer Patients nanCOMPLETED
DEFINITION OF THE GENOMIC LANDSCAPE OF MASLD nanRECRUITING
Novel Biomarkers in the Neoplastic Progression of Barrett's Esophagus nanACTIVE_NOT_RECRUITING
Aberrant Splicings Due to Microsatellite Instability in Colorectal Cancer : Physiopathological and Clinical Impact nanUNKNOWN
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy nanUNKNOWN
Molecular Studies on Hereditary Haemorrhagic Telangiectasia Families nanRECRUITING
Sialic Acid in Hepatocellular Carcinoma nanNOT_YET_RECRUITING
Predictive Value of Maternal Blood Protein Signatures in Preterm Birth nanCOMPLETED
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
Studying Tissue Samples From Patients With Stage II Colon Cancer Treated on Clinical Trial CLB-9581 nanCOMPLETED
Association of SNPs in Long Intergenic Noncoding RNA 00511 (LINC00511) With Breast Cancer Among the Egyptian Population nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a RBPJ binder may also engage these)

ProteinNameSimilarity
P31266 — 1.000 P31266 →
Q5RFK6 — 1.000 Q5RFK6 →
Q3SZ41 — 1.000 Q3SZ41 →
Q91880 — 1.000 Q91880 →
O76808 — 0.999 O76808 →
O02019 — 0.998 O02019 →
P28159 — 0.991 P28159 →
Q5FWH3 — 0.989 Q5FWH3 →
Q9UBG7 — 0.988 Q9UBG7 →
A2AF47 — 0.984 A2AF47 →
Q80TJ1 — 0.984 Q80TJ1 →
Q8N1G2 — 0.983 Q8N1G2 →
Q6GL65 — 0.983 Q6GL65 →
Q8BYR5 — 0.983 Q8BYR5 →
Q8TE85 — 0.983 Q8TE85 →
Q04207 — 0.983 Q04207 →
Q9ULU8 — 0.982 Q9ULU8 →
DOCK11 Dedicator of cytokinesis protein 11 0.982 landscape →
Q5R981 — 0.982 Q5R981 →
Q9DBC3 — 0.982 Q9DBC3 →
Q6GLR7 — 0.981 Q6GLR7 →
Q96BY6 — 0.981 Q96BY6 →
Q68EF0 — 0.981 Q68EF0 →
P42228 — 0.981 P42228 →
A7E2V1 — 0.981 A7E2V1 →
Q04865 — 0.981 Q04865 →
Q5PPL8 — 0.980 Q5PPL8 →
Q812E4 — 0.980 Q812E4 →
O08764 — 0.980 O08764 →
Q5EY87 — 0.980 Q5EY87 →